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ABSTRAK 
Kajian awal Induksi Toleransi Imun (ITI) dalam Rawatan 
Pediatrik Hemofilia A dengan Inhibitor 
Pengenalan 
Pembentukan antibodi terhadap Factor VIII konsentrat atau lebih dikenali sebagai 
inhibitor adalah salah satu komplikasi utama dalam perawatan untuk pesakit hemofilia 
A. Sejak 30 tahun yang lalu, Induksi Toleransi Imun (ITI) digunakan untuk menyahkan 
inhibitor dan memulihkan farmakokinetik factor VIII (FVIII) kepada normal. ITI 
adalah pilihan terbaik jangka panjang untuk menyahkan inhibitor, dengan kadar 
kejayaan yang tinggi dicapai antara 60% hingga 90%. Kajian ini bertujuan mengkaji 
demografi pesakit, ciri-ciri klinikal dan hasil toleransi terapi ITI di Pusat Darah  
Negara. 
 
Kaedah 
Kajian keratan rentas retrospektif telah dijalankan dengan mengumpulkan data 
sejumlah 18 pesakit kanak-kanak hemofilia A yang teruk dengan inhibitor yang 
menjalani ITI di Pusat Darah Negara daripada tahun 2002 sehingga 30 Jun 2016. Data 
– data berkaitan pesakit diambil daripada fail pesakit dan dimasukkan ke dalam borang 
kaji selidik yang telah diselaraskan.  Antara data yang diambil termasuk demografi 
pesakit, jenis gen mutasi FVII, jenis FVIII konsentrat, dos FVIII, sejarah paras puncak 
inhibitor pesakit, paras inhibitor pesakit sebelum, pada permulaan dan semasa 
perawatan ITI. ITI yang berjaya ditakrifkan apabila paras inhibitor telah negatif, aras 
xiii 
 
pemulihan FVIII kembali normal dan ketiadaan kesan amnestik apabila terdedah 
kepada rawatan FVIII berikutnya. 
 
Keputusan.  
Sejumlah 12 daripada 18 pesakit (66.6%) telah berjaya menyahkan inhibitor. Kajian ini 
juga menunjukkan terdapat statistik yang signifikan dengan sejarah paras inhibitor 
puncak sebelum memulakan terapi ITI (p = 0.015) , paras inhibitor sebelum ITI ( p = 
0.036), paras inhibitor ketika permulaan ITI (p = 0.010), paras puncak inhibitor semasa 
ITI (p = 0.018), dan tempoh antara pengesanan inhibitor sehingga ITI diberi dengan 
hasil akhir rawatan.  
 
Kesimpulan. 
Kajian ini menunjukkan bahawa terapi ITI boleh menjadi rawatan yang berkesan untuk 
menghapuskan inhibitor. Antara faktor-faktor kejayaan ITI termasuk sejarah paras 
puncak inhibitor yang rendah sebelum ITI (<200BU / ml), paras inhibitor yang rendah 
sebelum dan permulaan ITI(<10BU/ml). Tempoh yang lebih singkat untuk memulakan 
terapi ITI selepas pengesanan inhibitor juga mempengaruhi hasil rawatan ITI dengan 
kejayaan yang lebih tinggi. Oleh yang demikian, kajian ini merupakan kajian awal yang 
baik untuk memberi kefahaman dalam pemilihan pesakit mendapatkan rawatan ITI di 
Malaysiaagar hasil yang sukses dapat diperolehi.  
 
Kata kunci: hemofilia, inhibitor, factor VIII, induksi toleransi imun, paras inhibitor 
xiv 
 
ABSTRACT 
Preliminary Study of Immune Tolerance Induction in the Treatment of Paediatric 
Haemophilia A with Inhibitor 
 
Introduction 
One of the primary complications in the treatment of haemophilia A patient is the 
development of inhibitor. Over the last 30 years, Immune Tolerance Induction (ITI) has 
been used to eliminate inhibitor as well as to restore FVIII pharmacokinetics. ITI is the 
best long term device in eliminating inhibitors with its success rate varying from 60% 
to 90%.  The purpose of this study is to investigate the patient’s demography, clinical 
characteristics and the result from ITI therapy at the National Blood Centre. 
 
Method  
This cross sectional retrospective study is undertaken by reviewing the files of 18 
severe haemophilia A paediatric patients with inhibitors who underwent ITI therapy at 
the National Blood Centre from 2002 till June 2016. All information had been obtained 
from the patient’s file and entered into a standardized research proforma. The data were 
included patient’s demographics, type of FVIII gene mutation, type of FVIII product, 
FVIII dosing, inhibitor history, inhibitor level during ITI, duration of ITI therapy and 
the outcomes. The successful outcome was defined as negative titre inhibitors, FVIII 
level were normalized and no trace of amnestic upon subsequent FVIII exposure. 
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Result  
Twelve (66.6%) patients out of 18 from this study successfully eliminated inhibitors. 
This study also demonstrated that statistically there was a significant association with 
the historical peak inhibitor before start ITI (p = 0.015), peak of inhibitor during ITI (p 
= 0.018), inhibitor titre before ITI (p = 0.036), inhibitor at the start of ITI (p = 0.011) 
and the duration between inhibitor detection and the start of ITI (p = 0.046) with the 
final outcome of ITI therapy. 
 
Conclusion 
This study has demonstrated that ITI therapy can be an effective treatment and can be 
accepted as inhibitor eliminator. The successful ITI factors includes the history of low 
inhibitor titre peak prior to therapy (< 200BU/ml), low inhibitor titre peak during ITI, 
low inhibitor titre before and at the beginning of ITI (<10BU/ml). The shorter duration 
of starting ITI therapy after inhibitor detection could influence the ITI outcome with 
higher success rate. This is a good preliminary study that provides an understanding 
and helping the physicians in patient selection to start ITI therapy for a better success 
rate. 
 
Key words: haemophilia, factor VIII, inhibitor, immune tolerance induction, inhibitor 
titre 
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CHAPTER 1 
INTRODUCTION 
 
1.1  Overview of Haemophilia A 
Haemophilia A is an inherited X-linked genetic disorder, which is commonly 
reported as 1 in 5,000 of male live births worldwide (Mannucci and Franchini, 
2013). The World Federation of Haemophilia annual global surveys showed 
approximately 400,000 people had haemophilia across the world with 80% to 85% 
of them categorised as haemophilia A. The prevalence of haemophilia A in 
Malaysia was reported as 6.6 in 100,000 males (Stonebraker et al., 2010). In 2015, 
there were 2,677 cases of bleeding disorders registered in Haemostasis Laboratory 
in the National Blood Centre. Out of this number, a total of 1,157 cases (43.2%) 
were diagnosed as haemophilia A (unpublished data report on Haemorrhagic 
Disorder Registered with Haemostasis Laboratory, National Blood Centre, 2015).  
 
1.1.1 Pathophysiology of Haemophilia A 
Haemophilia is a rare bleeding disorder caused by lack or absence of coagulation 
factor that leads to improper blood clotting. Coagulation factor is a protein needed 
for normal blood clotting whereby in patients with haemophilia A, their factor VIII 
(FVIII) level is low as a result from the mutation of the particular clotting factor 
genes. The defect leads to disruption of the intrinsic coagulation cascade due to 
insufficient formation of the thrombin by the factor IX activated (FIXa) and factor 
VIII activated (FVIIIa) complex. As a result, patients are presented with 
spontaneous bleeding and/or excessive haemorrhage following to trauma (Kabel, 
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2014). The gene for FVIII is located on the long arm of the X chromosome.  Males 
from the maternal side are commonly affected as it inherited in an X-linked 
recessive pattern. However, about 30% of the cases show that an individual can 
have the disease without any family history of haemophilia which occurs due to 
spontaneous mutation (Mannucci and Tuddenham, 2001). 
 
1.1.2 Clinical Presentations of Haemophilia A 
Bleeding tendency is one of the most prominent clinical features in a haemophilia 
patient. They either present with spontaneous bleeding or following any trauma or 
surgery. The severity of bleeding manifestation in haemophilia is usually related to 
the FVIII levels in the patient’s plasma, as shown in Table 1.1. 
 
Table 1.1 Relationship of Bleeding Severity to Clotting Factor Level (Berntorp et 
al., 2011). 
Severity Clotting Factor Level Bleeding Episodes 
Severe  < 1 IU/dl (< 0.01 IU/ml) or  
 < 1 % of normal 
Spontaneous bleeding into joints or 
muscles, predominantly in the absence 
of any haemostatic causes. 
Moderate 1-5 IU/dl (0.01-0.05 IU/ml) or  
1-5% of normal 
Occasional spontaneous bleeding; 
prolonged bleeding with minor trauma 
or surgery 
Mild > 5-40 IU/dl (0.05-0.40 IU/ml) or 
 >5 to <40% of normal 
 
Severe bleeding with major trauma or 
surgery.  
Spontaneous bleeding is rare. 
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Most of the bleeding occurs in the joint and the muscle as shown in Table 1.2 and 
Table 1.3. Repeated joint bleed to the target joint will lead to chronic haemophilic 
arthropathy and cause morbidity to the patient. In severe cases of haemophilia A, the 
patient can also suffer from spontaneous life threatening bleeding tendencies such as 
intracranial bleed where immediate treatment is needed (Farrugia et al., 2012).  
Table1.2 Sites of Bleeding in Haemophilia (Hay et al., 2006). 
Serious  Joints (haemarthrosis) 
 Muscles, especially deep compartments (iliopsoas, calf, and 
forearm) 
 Mucous membranes in the mouth,  gums, nose, and genitourinary 
tract 
Life 
threatening 
 Intracranial 
 Neck/throat  
 Gastrointestinal 
 
Table 1.3 Approximate Bleeding Frequency at Different Sites (Srivastava et al., 2013). 
Sites Frequency (%) 
Haemarthrosis 
■ more common into hinged joints: ankles, knees, and elbows 
■ less common into multi-axial joints: shoulders, wrists, hips 
70%–80% 
 
Muscle 10% - 20% 
Other major bleeds 5% - 10% 
Central nervous system (CNS) < 5% 
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1.1.3 Diagnosis of Haemophilia A 
The principles to diagnose haemophilia A includes the understanding of clinical 
presentation followed by confirmation through laboratory findings (Srivastava et al., 
2013) . Complete blood count and coagulation profile which consist of prothrombin 
time (PT), and activated partial thromboplastin time (aPTT) are needed as a baseline in 
the patient with suggestive of haemophilia or other bleeding disorders. The diagnosis of 
haemophilia is usually suspected when the patient had isolated prolonged activated 
partial thromboplastin time (aPTT) and the confirmation of diagnosis is done by factor 
assays (Chalmers, 2004).  
 
1.1.4 Treatment of Haemophilia A 
The treatment of bleeding episodes for haemophilia depends on the sites of bleeding. 
The patient should be treated with relevant factor concentrate to the specific factor 
deficiency. Adequate replacement therapy includes adequate dose and adequate 
duration of factor coverage necessary to ensure the bleeding is well controlled, if 
possible within the two hours of the onset of symptoms (Srivastava et al., 2013). In the 
1950s other than whole blood, fresh plasma was the only blood product available to 
treat haemophilia. However, a large volume was required in order to get an adequate 
dose. A decade later, cryoprecipitate became available before plasma derived FVIII 
was discovered (Franchini and Mannucci, 2012). 
 
The patients also can recognize early symptoms of bleeding by a tingling sensation 
within the joint or known as ‘aura’ prior to the manifestation of overt signs of an acute 
5 
 
haemarthrosis (Alhaosawi, 2014).  Table 1.4 shows the standard dosage of an on 
demand therapy for haemophilia A based on the types of bleeding.  
Table 1.4 Suggested Plasma Factor Peak Level and Duration of Administration (When 
there is no significant resource Constraint) for On Demand Therapy (Srivastava et al., 
2013) 
 Haemophilia A 
Type of bleeding Desired Level (IU/kg) Duration (Days) 
Joint 40-60 1-2 , may longer if response is 
inadequate 
Superficial muscle / no 
neurovascular compromise 
(except iliopsoas) 
40-60 2-3 , sometimes longer if 
response is inadequate 
Iliopsoas and deep muscle with 
neurovascular injury or 
substantial blood loss 
80-100 (initial) 
30-60 (maintenance) 
 
1-2 
3-5, sometimes longer as 
secondary prophylaxis during 
physiotherapy. 
CNS / Head 80-100 (initial) 
50 (maintenance) 
1 -7 
8 -21 
Throat and neck 80-100 (initial) 
50 (maintenance) 
1 -7 
8 -14 
Gastrointestinal 80-100 (initial) 
50 (maintenance) 
1 -14 
Renal 50 3 -5 
Deep laceration 50 5 -7 
Surgery (Major) Pre-op (80 – 100) 
Post op (60-80) 
(40-60) 
(30-50) 
 
1 -3 
4 -6 
7-14 
Surgery (Minor) Pre-op (50 -80) 
Post-op (30-80) 
 
1-5 , depending on types of 
procedure 
 
 
6 
 
1.1.5 Complication of Replacement Therapy 
 
There are a few complications that may occur relating to the replacement therapy that 
includes antibody formation toward FVIII concentrate or known as inhibitor, which 
causes the bleeding to become more difficult to control and does not respond to the 
standard therapy(DiMichele et al., 2007a). In the past, there was also a risk of getting 
transfusion transmitted infection such as the hepatitis B virus, hepatitis C virus and 
Human Immunodeficiency virus from the blood products such as fresh frozen plasma, 
cryoprecipitate and the product from plasma derived FVIII concentrate (Franchini and 
Mannucci, 2012). However, the safety of the blood products has been improved in the 
last 25 years as all the blood donors were carefully screened, in addition to the plasma 
derived FVIII concentrate going through a serial viral inactivation during manufactured 
and the availability of the recombinant FVIII concentrate(Marwaha, 2013). Other than 
that, morbidity to the muscles, joints or other parts of the body due to delay in 
treatment (Fischer et al., 2002). 
 
1.2 Overview of Inhibitor Development 
Factor replacement therapy with FVIII concentrate is used to treat or prevent the 
bleeding episodes successfully in patients with haemophilia A. However, it can also 
cause severe complications associated with this replacement therapy which is the 
development of inhibitor towards FVIII (Coppola et al., 2010b).  Approximately 30% 
of patients with severe haemophilia A who received FVIII concentrate will have an 
inhibitor as the body recognizes it as a foreign antigen and stimulates the antibody 
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production (Berntorp et al., 2006). In Malaysia, about 10% of patients with 
haemophilia A had developed inhibitors in 2015 (Unpublished data report on 
Haemorrhagic Disorder Registered with Haemostasis Laboratory, National Blood 
Centre,2015). 
 
The patients with inhibitors mostly occurred in children (median age, 1.7 – 3.3 years), 
whose risk was higher in the first 50 days after the treatment doses are 
administered(DiMichele et al., 2007a). Other patient related factors that have been 
associated with the risk of inhibitor formation included ethnicity where the numbers are 
higher among the black compared to white patients (Viel et al., 2009). Patients with a 
family history of inhibitor also had threefold higher risk of development to this 
situation (Astermark et al., 2001). The factor VIII gene mutation type, human 
leukocyte antigen (HLA) complex genotype and polymorphism in genes involved in 
the regulation of the immune system also contributed to inhibitor formation (Astermark 
et al., 2006b). Presence of large gene defects such as inversion, insertion and deletion 
in multiple domains will caused reduction endogenous FVIII protein synthesis, and 
once the exogenous FVIII infused, the body will recognize as foreign protein and lead 
to production of alloantibodies or known as a FVIII inhibitor (Oldenburg and Schwaab, 
2001). Environmental factors such as the age of first exposure, intensive FVIII usage 
during infancy, immunologic challenges such as infection, surgery and immunizations 
or types of factor concentrate used (recombinant or plasma derived) also play a role in 
inhibitor development but the aetiology process is still debatable (Gouw et al., 2007). 
 
 
8 
 
1.2.1 Method of Analysis for Inhibitor Development 
The presence of inhibitor was suspected when the prolonged aPTT was not fully 
corrected by the mixing test (Srivastava et al., 2013). The Bethesda assay is used to 
determine the inhibitor levels and the titres are measured in Bethesda Unit (BU). 
Inhibitors are classified into a high titre when the titre is equal to or more than 5 
Bethesda Unit, whereas a low titre is defined when the titre is less than 5 Bethesda Unit 
(Kempton and White, 2009).  
 
1.3 Overview Management of Inhibitor 
The presence of inhibitors does not increase mortality, yet it will complicate the 
treatment outcome as it does not respond to the standard therapy.  Consequently, the 
bleeding is difficult to control, increase the morbidity and increase the factor usage in 
treatment (Hay et al., 2000). To overcome this problem, patients with transient or low 
titre inhibitors can be managed by giving them higher doses of FVIII concentrate 
(Peerlinck and Hermans, 2006). However, for those with high titre inhibitor the 
standard FVIII replacement therapy was found to be ineffective and bypassing agents is 
required to treat the bleeding episodes such as recombinant activated factor VII 
(rFVIIa) or an activated prothrombin complex concentrates (aPCC ) (Paisley et al., 
2003). The patient is considered as a low responding inhibitor when the antibody titre 
never exceeded 5BU even after being repeatedly exposed to the FVIII.  A high 
responding inhibitor is considered when the patients has an inhibitor titre that exceeds  
≥ 5BU at least once and after being repeatedly exposed to FVIII as the immune systems 
will rapidly trigger new inhibitor formation (Leissinger, 2004). 
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For the past 30 years, the immune tolerance induction (ITI) therapy has been used to 
eliminate inhibitors particularly for high titres antibodies. Immune tolerance induction 
(ITI) therapy is generally comprised of factor concentrate which is given regularly over 
a period of time until the immune system is tolerant to the antigen and preventing 
further antibodies production. Once the ITI is successful, the inhibitors are eliminated 
and the patient’s response to factor concentrates is reverted back to normal (Ho et al., 
2000).  
 
ITI remains the best long term option to eradicate inhibitors, with success rate varying 
between 60% to 80% (Wight et al., 2003). The first ITI protocol, known as the Bonn 
protocol was described in 1977 by Brackmann and Gormsen which required 
administering high doses of FVIII ≥200IU/kg on a daily basis (Brackmann and 
Gormsen, 1977). There are also other protocol that evolved based on low doses of 
FVIII and administration of non-specific therapies such as steroid, cyclophosphamide, 
high doses of intravenous immunoglobulins or extra corporeal immunoadsorption 
(Wight et al., 2003) . However, there are still variations in the outcomes and time 
required to achieve tolerance in the various studies as shown in the table 1.5.  
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Table 1.5 Characteristics and Outcome of Reported ITI Protocol (Coppola et al., 
2010a) 
ITI protocol FVIII dose and 
associated treatment 
Success 
rate (%) 
Median 
time to 
success, 
months 
Comments 
Bonn protocol 
(high-dose 
regimen)* 
 
FVIII 100–150 iu/kg every 12 h until 
inhibitor <1 BU, 
then FVIII 150 iu/kg until normalization of 
FVIII recovery and half-life 
 
92–100 14 Very demanding 
for patients.  
High cost 
Malmo  protocol 
(high-dose 
regimen & 
immune 
modulation)** 
 
FVIII continuous infusion targeting plasma 
levels >30 iu/dl until negative inhibitor titre,  
then 60–90 iu/kg weekly + cyclophosphamide 
(i.v. 12–15 mg/kg days 1–2,  
2–3 mg/kg orally days 3–10) + i.v. 
immunoglobulins 2.5–5 g/kg day 1, 
 0.4 g/kg days 4–8. 
Preliminary protein A sepharose 
immunoadsorption if initial inhibitor titre >10 
BU. 
 
59-82 1 Rapid response 
and cost-saving but 
need for 
hospitalization 
and concerns 
regarding the 
use of 
cyclophosphamide 
in children 
Dutch protocol 
(low-dose 
regimen)*** 
Neutralizing dose (25–50 iu/kg twice daily, 
1–2 weeks), then tolerizing dose (50–75 iu/kg 
weekly) 
 
61-88 1-12 Less demanding 
for patients and 
cost-saving 
Other low or 
intermediate dose 
protocols 
Ewing et al, 1988: 50 iu/kg/d 67 2 Developed for 
improving 
cost-effectiveness 
of treatment 
Kucharski et al, 1996: 50 iu/kg/week 45 10 
Unuvar et al, 2000: 50–100 iu/kg/d 57 6 
Rocino et al, 2001: 100 iu/kg/d 75 8 
*(Brackmann et al., 1996) and (Oldenburg et al., 1999); activated prothrombin complex concentrates (aPCC) 40–60 
iu/kg every 12 h was included until 1996. 
**(Nilsson et al., 1988) and (Freiburghaus et al., 1999) 
***(Mauser-Bunschoten et al., 1995)  
 
Most of the current practice is determined by the clinician choice, expert view, 
experience, recommendation from the published guidelines and local setting at each 
haemophilia centre (Robertson et al., 2014). Thus, it is important to understand the 
factor that is associated with the successful immune tolerance therapy because ITI 
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therapy is very expensive and not many patients have the opportunity to be offered with 
this treatment. 
  
In Malaysia, there is no standard ITI protocol used nationwide. Furthermore, due to 
cost constraints, it causes the ITI therapy inaccessible to many patients. Hopefully, by 
understanding the factors that may influence the likelihood of a successful ITI, the 
selection of patients who will or will not benefit from ITI can be determined and 
provide a better success rate. This can be determined by knowing the character of FVIII 
inhibitors in patients with ITI therapy and the treatment related factors that are 
associated with the duration and outcome of the therapy. 
 
1.4 Justification and Benefits of Research Study 
The risk of inhibitor formation is higher after 10 to 15 exposure days of FVIII 
concentrate thus, the children are more prone to develop an inhibitor (Wight and 
Paisley, 2003). The inhibitor development also more common in patients with 
haemophilia A compared to haemophilia B(Carcao and Lambert, 2010) and those who 
had classified as severe (FVIII level less than 1 %) haemophilia compared to moderate 
or mild type.(Mannucci and Tuddenham, 2001). 
 
A patient with severe haemophilia A with inhibitor is at risk of uncontrolled bleeding, 
extensive joint disease and joint disability (Morfini et al., 2007). Immune tolerance 
induction (ITI) is the best approach to eliminate inhibitors. This may reduce the risk of 
bleeding and improved the quality of life. However, up to the best of our knowledge, 
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there was no standard ITI protocol in Malaysia. Most of the data on the ITI protocol for 
haemophilia A available are from the international studies.  Based on the published 
data several predictors of ITI can be used to guide in the selection of inhibitor patients 
for better outcome and reduce wastage of resources. 
 
ITI therapy was started in NBCKL since 2002 and the protocol is used based on the 
international ITI recommendation. However, the main hindrance for patients to receive 
ITI therapy was included the cost, availability of factor concentrate, good venous 
access and the commitment from the patients and the family members. Till December 
2015 only 18 out of 25 paediatric patients with inhibitor had undergone ITI therapy. 
Thus, this study is needed to look at the current ITI protocol and to identify factors that 
can influence the treatment outcomes. Based on the findings from this study, a 
comparable data can be made in the future. Furthermore, with a higher success rate 
achieved with the current ITI protocol a standard ITI protocol can be recommended as 
guidance for other treatment centre, especially in Malaysia. 
 
Therefore, from this preliminary study, it provides an evidence and understanding for 
selection of patients to start ITI therapy in Malaysia. This could help the clinicians to 
decide when is the best time to start immune tolerization, the appropriate dosing and 
choice of FVIII product for a better outcome. By getting the best and optimal ITI 
therapy with a good patient selection better outcome will be achieved and reduce waste 
of resources. 
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1.5 Objectives of Research Study 
 
1.5.1 General Objective 
 
To study the factors associated with outcomes of immune tolerance induction therapy 
among paediatric severe haemophilia A with inhibitor in National Blood Center, Kuala 
Lumpur. 
 
1.5.2 Specific Objectives 
 
a) To describe the demographics and clinical characteristics in patients on ITI 
therapy. 
b) To describe the proportion of treatment outcomes among patient who had 
undergone the immune tolerance induction therapy.  
c) To determine the factors associated with success, partial success or failed of 
immune tolerance induction therapy. 
 
1.6 Hypothesis of Research Study 
 There are associations between patient with low titre inhibitor prior and at start 
of ITI with successful outcome of immune tolerance induction therapy. 
 There is an association between younger age group that recently develop 
inhibitor with successful outcome of immune tolerance induction therapy. 
 There is an association between patients who had received higher doses of 
FVIII with successful outcome of immune tolerance induction therapy. 
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1.7 Conceptual Framework 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Conceptual Framework for the Study 
Patient characteristics:  
-Ethnicity 
-Age at inhibitor detection 
- Age at start ITI 
-FVIII gene mutation 
  
 
 
 
 
 
 
 
 
Inhibitor titre level (BU/ml) 
-Historical peak inhibitor 
titre  
- Inhibitor prior to ITI 
-Inhibitor titre at start of 
ITI 
- peak inhibitor during ITI 
 
 
 
 
 
 
 
Treatment during ITI 
-  FVIII dosing 
-Type of FVIII concentrate 
- Duration for ITI 
 
 
 
 
 
 
 
 
Outcomes 
Patients diagnosed as severe haemophilia A with 
inhibitor 
Received ITI therapy in National 
Blood Centre, Kuala Lumpur 
Partial Success Failed Success 
Did not received ITI therapy 
in National Blood Centre, 
Kuala Lumpur 
15 
 
CHAPTER 2 
Literature Review 
 
2.1 Treatment for Haemophilia A 
Congenital haemophilia A is an X-linked and rare bleeding disorder due to a deficiency 
of factor VIII (FVIII) (Mannucci and Tuddenham, 2001).  FVIII is one of the 
coagulation protein needed for blood to clot properly. In severe haemophilia cases 
(factor VIII level is a situation when a patient’s plasma is lees than 1%) , the patient 
can have bleeding episodes as frequently as 20 to 30 times per year and life threatening 
bleeding like intracranial bleeds also may occur (Farrugia et al., 2012). Haemophilia 
arthropathy is the major morbidity in patients with haemophilia as a result of recurrent 
bleeding episodes into joint space (Leslie and Catherine, 2007). The patients will be 
presented with synovial hypertrophy, narrow joint space, cartilage damage and bony 
destruction (Pipe and Valentino, 2007). 
 
In 1950s, haemophilia A patients were treated with only whole blood or fresh plasma. 
However, the inadequate FVIII coagulation factor in these blood products makes the 
bleeding difficult to stop especially in major bleeds. Therefore, most of the severe 
haemophilia A patients had lower life expectancy and died during childhood or early 
adulthood (Franchini and Mannucci, 2012). The treatment evolution started from the 
1960s when factor concentrate was discovered, which contained a large amount of 
factor VIII (Franchini and Mannucci, 2012). Since then, factor replacement has become 
the basis of treatment for bleeding episodes. Adequate replacement therapy with 
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specific factor is important to ensure that the bleeding episodes and joint deformities 
can be prevented (Liesner et al., 1996). 
 
Haemophilia A patients usually requires lifelong FVIII replacement therapy to prevent 
and treat the bleeding episodes. A survey done in 2006 consist of 147 haemophilia 
treatment centres from United States, Canada, Australia, Sweden, Belgium, Brazil, 
Finland, Hungary, Iceland, Israel, Japan, Malaysia, Mexico, Holland, New Zealand, 
South Africa, Spain and Taiwan, which involved 16115 patients with haemophilia A. 
This survey showed about 54% of patients were on demand therapy compared to 37% 
of patient who had received prophylaxis therapy(Geraghty et al., 2006). These data 
shows that most of the patients with severe haemophilia A in the countries surveyed are 
still treated as on demand therapy, where the factor replacement is only given during 
the presence of acute bleeding although it is recommended by the World Health 
Organisation (WHO) to administer prophylaxis instead(Geraghty et al., 2006). Other 
than that, some haemophilia patients especially in developing countries like Malaysia 
will be underdiagnosed due to limited and less optimal treatment available. Only 25% 
of patients had an access to the treatments (Ayob, 2008). 
 
The concept of prophylaxis in haemophilia A using FVIII concentrate to prevent and 
reduce the frequency of bleeding was first introduced in Sweden at the Malmo Centre 
in 1958 by Nilsson and a team of researchers (Ljung, 2009). However, the factor 
concentrate was not easily available and the dosage given at that time was relatively 
small.  FVIII concentrate was administered once in 14 days when it was first 
introduced. Over the years with sufficient amount of factor concentrate available, 
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prophylaxis was given every 2 to 4 weeks which was then increased to three times a 
week (Carcao, 2014). Most of the studies done showed that prophylaxis treatment had a 
better short and long term outcome either by primary or secondary prophylaxis. Based 
on two randomized controlled trial (Manco-Johnson, 2007; Gringeri et al., 2011) their 
study's outcome showed there is a significant reduction in the frequency of bleeding 
and had improved quality of life, although it did not reverse the joint that have already 
been damaged in a patient who was treated with prophylaxis compared to those on 
demand therapy. 
 
Even though most of the published studies showed prophylaxis was an ideal therapy as 
recommended by the World Federation of Haemophilia and World Health 
Organization, unfortunately in many countries it is still not widely applied (Manco-
Johnson, 2003). Several barriers related to this problem in starting an early and long 
term prophylaxis treatment especially in children included the availability of factor 
concentrate, the cost, the understanding about the need of prophylaxis and insecurities 
pertaining to the possible complications related to the treatment (Petrini et al., 2004). 
 
The management of haemophilia is complex and the treatment depends on clinical 
diagnosis, good laboratory facilities and the availability of factor replacement therapy. 
A comprehensive care clinic is the best setting to manage haemophilia patients, which 
involves a multidisciplinary team including doctors, nurses, physiotherapist, dentist and 
also psychologist (Ayob, 2008). A study conducted by US Centres for Disease Control 
and Prevention (CDC) had shown that patients who had been managed in 
comprehensive care centres had lower mortality (1:1.6) and less hospitalisation 
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episodes compared to patients who had been managed by individual physicians or 
haematologist (Poon and Card, 2012).  
 
2.2 Treatment of Haemophilia A with Inhibitor. 
The availability of FVIII concentrate has led to a greater impact in the health status and 
joint outcomes in patient that suffered from haemophilia A. However, the development 
of antibody towards exogenous FVIII known as an inhibitor caused the most severe 
complications of replacement therapy in patients with haemophilia A. Inhibitors was 
commonly seen in patient with severe haemophilia A compared to haemophilia B or 
mild/moderate haemophilia patients(Mannucci and Tuddenham, 2001). The risk of 
inhibitor is also higher in children with severe haemophilia especially after 10 to 15 
exposure days to FVIII concentrate (Wight and Paisley, 2003). The other factors that 
had increased the risk of inhibitor development included a patient with a family history 
of inhibitor or African- American descent (Astermark et al., 2001; Mannucci and 
Tuddenham, 2001). 
 
Inhibitor formations cause the replacement therapy to become ineffective, more 
challenging to achieve haemostasis that leads the bleeding becoming difficult to 
control. The presence of inhibitors also have an impact on patient’s physical activity, 
morbidity thus decreasing the quality of life as patients had missed from school or work 
due to bleeding episodes (Brown et al., 2009). Approximately, 20% to 30% of patients 
with severe Haemophilia A had developed inhibitors compared to haemophilia B (less 
than 5%) (Astermark et al., 2006b). 
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The inhibitor formation should be suspected when there is a poor clinical response 
during any bleeding episodes or following any surgery despite a standard dose of FVIII 
infusion. Once an inhibitor is suspected, the laboratory test using a Bethasda Inhibitor 
Assay (BIA) should be carried out. Most of the screening test for inhibitors is done 
prior to any surgical procedure or monitored within the first 50 days of exposure 
(Kempton and White, 2009). The inhibitor will bind to the FVIII and prevent its 
haemostatic action and resulting in the bleeding becoming difficult to control and 
makes the surgery more hazardous (Darby et al., 2004). 
 
Low titre inhibitor is defined when the titre reading is ≤ 5BU and it can usually can be 
treated with larger doses of factor VIII concentrate. However, those with high titre 
inhibitor (>5BU) will usually render the replacement therapy ineffective in treating 
acute bleeding episodes and requires a bypassing therapy (Hay et al., 2000). Currently, 
there are two bypassing agents available worldwide that include the recombinant factor 
VIIa (rFVIIa), NovoSeven or activated prothrombin complex concentrate (aPCC) and 
factor eight inhibitor bypassing activity (FEIBA). Generally, both products had similar 
efficacy which ranges from 80% to 90%. Since the agents will promote thrombin 
formation by a different mechanism, thus it believed that the action of both agents 
might be variations in individual cases (Coppola et al., 2010a). The rfVIIa acts directly 
on the platelet surface by activating factor X, thus bypassing the tenase complex 
(Roberts et al., 2004). FEIBA is a plasma derived of vitamin K-dependent clotting 
factors (factor II, factor VII, factor IX, factor X and others) that acts by boosting 
activity of the prothrombinase complex (Turecek et al., 1999).  rFVIIa is a recombinant 
product and does not have FVIII, thus, rFVIIa has no tendency to anamnesis to FVIII 
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and is usually used as the initial therapy in treating acute bleeding episodes in patients 
with inhibitors that do not respond to FVIII anymore. The half-life for rFVIIa is 2.3 
hours in adult and even shorter in children and it is commonly given in standard doses 
of 90 to 120 mcg/kg every 2 to 3 hours for the usual joint bleed (Kempton and White, 
2009). A study done by Iorio et al , from two RCTs of rFVIIa and  aPCC showed that 
both products can be given as a single bolus infusion and had a low level of 
thromboembolic risk (Iorio et al., 2010). 
 
There were three (3) prospective studies carried out using bypassing agents as 
prophylaxis in an inhibitor patient and the result showed that those on rFVIIa and aPCC 
prophylaxis had significant reduction in bleeding frequency and improved quality of 
life compared with on demand therapy (Leissinger et al., 2015). The inhibitor patients 
also had fewer hospital admissions, days missing from school or work and no 
thromboembolic event reported while patients are on prophylaxis therapy. Even though 
prophylaxis using bypassing agents is the treatment option to reduce morbidity in 
patients who had persistently high titres inhibitors or planned for immune tolerance 
induction therapy, the major barrier in choosing this the treatment is the cost and lack 
of accessibility (Kempton and Meeks, 2014). The other factor that needs to be 
considered when starting prophylaxis using bypassing agents is to either use rFVIIa or 
FEIBA that includes; the frequency of infusion, volume of infusion and anamnestic 
response (Kempton and White, 2009). 
 
 
